Charles Schwab Investment Management Inc Prometheus Biosciences, Inc. Transaction History

Charles Schwab Investment Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$103.46 - $126.29 $38,280 - $46,727	-370 Reduced 0.14%	255,928 $27.5 Million
Q4 2022 Feb 13, 2023	BUY	$36.06 - $117.21 $1.51 Million - $4.89 Million	41,750 Added 19.46%	256,298 $28.2 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $2.75 Million - $5.76 Million	97,546 Added 83.37%	214,548 $12.7 Million
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $83,940 - $145,986	-3,749 Reduced 3.1%	117,002 $3.3 Million
Q1 2022 May 13, 2022	BUY	$30.13 - $50.0 $94,035 - $156,050	3,121 Added 2.65%	120,751 $4.56 Million
Q4 2021 Feb 11, 2022	BUY	$22.28 - $39.54 $933,955 - $1.66 Million	41,919 Added 55.37%	117,630 $4.65 Million
Q3 2021 Nov 16, 2021	BUY	$20.89 - $26.96 $12,178 - $15,717	583 Added 0.78%	75,711 $1.8 Million
Q2 2021 Aug 16, 2021	BUY	$16.8 - $29.65 $1.26 Million - $2.23 Million	75,128 New	75,128 $1.85 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.